mirvetuximab soravtansine

Details

Files
Generic Name:
mirvetuximab soravtansine
Project Status:
Active
Therapeutic Area:
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0394-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with folate receptor-alpha (FR) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
​For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openJanuary 17, 2025
Call for patient/clinician input closedMarch 18, 2025
Submission receivedMarch 03, 2025
Submission acceptedMarch 18, 2025
Review initiatedMarch 19, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 13, 2025
Deadline for sponsors commentsJune 24, 2025
CADTH review report(s) and responses to comments provided to sponsorJuly 31, 2025
Expert committee meeting (initial)August 13, 2025
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedbackSeptember 04, 2025
End of feedback periodSeptember 18, 2025